Marimastat Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:342128043
Iupac Name:N-[2,2-Dimethyl-1-(methylcarbamoyl)propyl]-2-[hydroxy-(hydroxycarbamoyl)methyl]-4- methyl-pentanamide
Legal Status:Development terminated?
Routes Of Administration:By mouth
Iuphar Ligand:5220
Cas Number:154039-60-8
Atc Prefix:None
Pubchem:119031
Drugbank:DB00786
Chemspiderid:106358
Unii:D5EQV23TDS
Chembl:279785
Pdb Ligand:097
C:15
H:29
N:3
O:5
Smiles:O=C(NO)[C@@H](O)[C@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CC(C)C
Stdinchi:1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1
Stdinchikey:OCSMOTCMPXTDND-OUAUKWLOSA-N

Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.[1] [2]

Marimastat performed poorly in clinical trials,[3] and development was terminated. This may be, however, a result of targeting cancer at too late of a stage. This is supported by the fact that MMP inhibitors have more recently been shown in animal models to be more effective in earlier stages of cancers. (Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812. Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., and Hanahan, D. (1999)).

See also

Notes and References

  1. Web site: Marimastat. National Cancer Institute.
  2. Millar AW, Brown PD, Moore J, Galloway WA, Cornish AG, Lenehan TJ, Lynch KP . Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers . British Journal of Clinical Pharmacology . 45 . 1 . 21–6 . January 1998 . 9489589 . 1873993 . 10.1046/j.1365-2125.1998.00639.x .
  3. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE . Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196 . Journal of Clinical Oncology . 22 . 23 . 4683–90 . December 2004 . 15570070 . 10.1200/JCO.2004.08.054 . free .